Richard Newmark

3.1k total citations · 1 hit paper
16 papers, 2.4k citations indexed

About

Richard Newmark is a scholar working on Rheumatology, Hematology and Immunology. According to data from OpenAlex, Richard Newmark has authored 16 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Rheumatology, 7 papers in Hematology and 6 papers in Immunology. Recurrent topics in Richard Newmark's work include Rheumatoid Arthritis Research and Therapies (9 papers), Autoimmune and Inflammatory Disorders Research (7 papers) and Psoriasis: Treatment and Pathogenesis (5 papers). Richard Newmark is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (9 papers), Autoimmune and Inflammatory Disorders Research (7 papers) and Psoriasis: Treatment and Pathogenesis (5 papers). Richard Newmark collaborates with scholars based in United States, Canada and Australia. Richard Newmark's co-authors include Stanley Cohen, Mark C. Genovese, Wayne Tsuji, Sean Robbins, Robin K. Dore, Lifen Zhou, Nancy E. Lane, P A Ory, Larry W. Moreland and Pirow Bekker and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Journal of Bone and Mineral Research.

In The Last Decade

Richard Newmark

16 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease

2016 289 citations Stephan R. Targan, Brian G. Feagan et al. The American Journal of Gastroenterology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard Newmark United States	13	1.1k	873	793	766	595	16	2.4k
Wayne Tsuji United States	22	2.9k 2.6×	1.4k 1.6×	576 0.7×	415 0.5×	479 0.8×	26	3.7k
Serena Bugatti Italy	28	1.3k 1.2×	655 0.8×	258 0.3×	289 0.4×	87 0.1×	89	2.1k
C. Stach Germany	19	1.5k 1.4×	1.2k 1.4×	280 0.4×	140 0.2×	178 0.3×	45	2.2k
Marijn Vis Netherlands	20	997 0.9×	498 0.6×	243 0.3×	132 0.2×	233 0.4×	68	1.5k
Dimitrios Daoussis Greece	26	872 0.8×	529 0.6×	423 0.5×	224 0.3×	102 0.2×	93	2.4k
Valérie Devauchelle France	26	874 0.8×	876 1.0×	280 0.4×	312 0.4×	58 0.1×	57	2.2k
William Shergy United States	19	1.2k 1.1×	561 0.6×	228 0.3×	213 0.3×	125 0.2×	24	1.9k
Bert Vander Cruyssen Belgium	26	1.4k 1.3×	615 0.7×	261 0.3×	128 0.2×	152 0.3×	61	2.2k
Anna Filipowicz‐Sosnowska Poland	8	1.8k 1.6×	1.1k 1.2×	344 0.4×	345 0.5×	50 0.1×	36	3.4k
Jennifer M. Grossman United States	15	874 0.8×	494 0.6×	251 0.3×	263 0.3×	271 0.5×	16	1.5k

Countries citing papers authored by Richard Newmark

Since Specialization

Citations

This map shows the geographic impact of Richard Newmark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Newmark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Newmark more than expected).

Fields of papers citing papers by Richard Newmark

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Newmark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Newmark. The network helps show where Richard Newmark may publish in the future.

Co-authorship network of co-authors of Richard Newmark

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Newmark. A scholar is included among the top collaborators of Richard Newmark based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Newmark. Richard Newmark is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Targan, Stephan R., Brian G. Feagan, Séverine Vermeire, et al.. (2016). A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease. The American Journal of Gastroenterology. 111(11). 1599–1607. 289 indexed citations breakdown →

Pavelká, Karel, Yun Chon, Richard Newmark, et al.. (2015). A Study to Evaluate the Safety, Tolerability, and Efficacy of Brodalumab in Subjects with Rheumatoid Arthritis and an Inadequate Response to Methotrexate. The Journal of Rheumatology. 42(6). 912–919. 65 indexed citations

Mease, Philip J., Mark C. Genovese, Maria Greenwald, et al.. (2015). OP0175 Two-Year Clinical Response to Brodalumab, An Anti-IL-17 Receptor Antibody, in Patients with Psoriatic Arthritis. Annals of the Rheumatic Diseases. 74. 136–137. 4 indexed citations

Mease, Philip J., Mark C. Genovese, Maria Greenwald, et al.. (2014). Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis. New England Journal of Medicine. 370(24). 2295–2306. 308 indexed citations

Genovese, Mark C., Philip J. Mease, Maria Greenwald, et al.. (2014). AB0752 Efficacy and Safety of Brodalumab over One Year in Patients with Psoriatic Arthritis with and without Prior Exposure to A Biologic. Annals of the Rheumatic Diseases. 73. 1052–1053. 4 indexed citations

Genovese, M. C., Maria Greenwald, Christopher T. Ritchlin, et al.. (2013). OP0103 Efficacy of Brodalumab, an Anti-IL-17R Antibody, in Subjects with Psoriatic Arthritis. Annals of the Rheumatic Diseases. 72. A85–A85. 6 indexed citations

Targan, Stephan R., Brian G. Feagan, Séverine Vermeire, et al.. (2012). Mo2083 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease. Gastroenterology. 143(3). e26–e26. 73 indexed citations

Deodhar, Atul, Robin K. Dore, David R. Mandel, et al.. (2010). Denosumab‐mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care & Research. 62(4). 569–574. 96 indexed citations

Sharp, John T., et al.. (2010). Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis. Arthritis Care & Research. 62(4). 537–544. 49 indexed citations

10.

Dore, Robin K., Stanley Cohen, Nancy E. Lane, et al.. (2009). Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Annals of the Rheumatic Diseases. 69(5). 872–875. 138 indexed citations

11.

Brown, Jacques P., Richard L. Prince, Chad Deal, et al.. (2008). Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial. Journal of Bone and Mineral Research. 24(1). 153–161. 436 indexed citations

12.

Cohen, Stanley, Robin K. Dore, Nancy E. Lane, et al.. (2008). Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, phase II clinical trial. Arthritis & Rheumatism. 58(5). 1299–1309. 435 indexed citations

13.

Genovese, Mark C., Stanley Cohen, Larry W. Moreland, et al.. (2004). Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis & Rheumatism. 50(5). 1412–1419. 385 indexed citations

14.

Bresnihan, Barry, Richard Newmark, Sean Robbins, & Harry K. Genant. (2004). Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial.. PubMed. 31(6). 1103–11. 67 indexed citations

15.

Genovese, Mark C., Shira Cohen, D E Furst, et al.. (2001). Safety Of Combination Therapy With Anakinra And Etanercept In Patients With Rheumatoid Arthritis.. Arthritis & Rheumatism. 44(9). 23 indexed citations

16.

Newmark, Richard, et al.. (2000). The influence of the resolution and contrast on measuring the articular cartilage volume in magnetic resonance images. Magnetic Resonance Imaging. 18(8). 965–972. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact